ACAAI Annual Scientific Meeting - American College of Allergy, Asthma & Immunology Annual Scientific Meeting

home / conference / acaai-annual-scientific-meeting-american-college-of-allergy-asthma-and-immunology-annual

Dupixent (dupilumab) injection -- Image credit: Matthew | stock.adobe.com

Dupilumab Shows Significant Reductions in Itch and Hive Activity in Patients With CSU

Gillian McGovern, Associate Editor

November 5th 2024

About 41% and 30% of patients with chronic spontaneous urticaria (CSU), respectively, achieved well-controlled disease status and complete response when treated with dupilumab.

Do Not Sell My Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777